Simulations Plus (SLP)

Executive Summary

Simulations Plus is a leading biosimulation software and consulting firm serving the pharmaceutical, biotechnology, and regulatory sectors. The company’s core offerings include physiologically based pharmacokinetic (PBPK) modeling, pharmacometrics, and quantitative systems pharmacology (QSP) solutions, increasingly integrated with AI and machine learning. These tools help clients predict drug behavior—absorption, distribution, metabolism, excretion, and toxicity (ADMET)—as well as efficacy, thereby reducing R&D costs and accelerating timelines. Founded in 1996 and publicly traded (NASDAQ: SLP), the company has established a strong reputation among top pharma firms and regulators, including the FDA, which frequently references Simulations Plus’s software in guidance documents. With a market capitalization around $335 million, Simulations Plus continues to benefit from the industry’s push toward model-informed drug development (MIDD) and digitalization of R&D. The company’s subscription-based model and recurring revenue from scientific consulting provide a stable financial base while ongoing investments in AI aim to expand its competitive moat.

Upcoming Catalysts (preview)

• Q3 2026FDA Final Guidance on PBPK Modeling for Generic Drugs80% success
• Q4 2026Launch of Next-Gen AI-Integrated Biosimulation Platform65% success
• Q2 2026Major Pharma Partnership or License Deal70% success